The Clinical Core provides Hawaii and Pacific Rim patients with accurate and early diagnostic cognitive evaluations and treatment trials. Patients are provided with advanced neuroimaging modalities interpreted under the mandate of national protocols and standards. The Clinical cores function is to differentiate dementia types including those with normal aging processes with an emphasis on early diagnosis and preventive measures. The Clinical Core connects well-diagnosed research participants with researchers conducting clinical trials and scientific studies at the HADC and other ADCs and matches them with the most appropiate research projects.
The Tissue Core collects Information on HADC patient and organize them in a systematic manner that facilitates its use by collaborating
physicians and scientists throughout the world. Effort is made to identify markers of dementia from its earliest onset to its later stages. Biomarkers may include genes, proteins, or other metabolites identified in DNA, cerebrospinal fluid (CSF), or plasma including Apolipoprotein E (APOE) genotype. Tissue core also maintains a "brain bank" with valuable information to understand the progression of Alzheimer’s disease, from its earliest onset to its latest stages, and to contribute to finding a cure.
The Education Core serves as a teaching site for doctors, scientists and other health care professionals involved in the care of dementia patients to emphasize early and accurate diagnosis and appropriate treatments. HADC provides a compassionate comprehensive assessment of
the social needs of the patients and their caregivers with dementia. Life enrichment programs are provided to improve quality of life for
persons with dementia and support their family and caregivers. HADC facilitates the development of innovative care strategies and investigates the impact of living with Alzheimer’s disease and related disorders in Hawaii and the Pacific Islands, with a particular focus on under served populations.